Aquablation治疗大体积前列腺(80-150 cc)良性前列腺增生:1年结果
这项前瞻性多中心国际临床试验纳入101例有中重度症状且前列腺体积80-150 cc的良性前列腺增生男性,接受机器人辅助Aquablation手术。术后12个月,国际前列腺症状评分从基线23.2降至6.2(P<.0001),生活质量评分从4.6降至1.3(P<.0001),最大尿流率和残余尿量均显著改善。作者认为该手术在大前列腺患者中安全有效,并发症率可接受。
要点
- 术后12个月国际前列腺症状评分从基线23.2降至6.2(P<.0001)
- 生活质量评分从基线4.6降至12个月1.3(P<.0001)
- 81%性活跃男性维持顺行射精,无患者因BPH症状再次手术
核心结论
- Aquablation手术在随访1年时对治疗大前列腺(80-150 cc)男性被证明安全有效,并发症率可接受,且与较小腺体相比手术或切除时间无显著增加。
研究设计与样本
- 前瞻性多中心国际临床试验,纳入101例有中重度BPH症状且前列腺体积80-150 cc的男性,接受机器人辅助Aquablation手术,评估术后12个月的功能与安全性结局。
主要发现
- 平均前列腺体积107 cc(范围80-150),平均手术时间37分钟,平均Aquablation切除时间8分钟,平均住院时间1.6天。
- 平均国际前列腺症状评分从基线23.2改善至12个月6.2(P<.0001),生活质量评分从4.6改善至1.3(P<.0001)。
- Qmax在12个月改善12.5 cc/sec,基线残余尿量>100 cc者残余尿量下降171 cc。
- 81%性活跃男性维持顺行射精,无患者因BPH症状接受再次手术;12个月新发尿失禁率2%,10例术后需输血,5例需再次电凝止血。
- 12个月前列腺特异性抗原从基线7.1 ± 5.9 ng/mL降至4.4 ± 4.3 ng/mL。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report 12-month safety and effectiveness outcomes of the Aquablation procedure for the treatment of men with symptomatic benign prostatic hyperplasia (BPH) and large-volume prostates. METHODS: One hundred and one men with moderate-to-severe BPH symptoms and prostate volumes of 80-150 cc underwent a robotic-assisted Aquablation procedure in a prospective multicenter international clinical trial. Functional and safety outcomes were assessed at 12 months postoperatively. RESULTS: Mean prostate volume was 107 cc (range 80-150). Mean operative time was 37 minutes and mean Aquablation resection time was 8 minutes. The average length of hospital stay following the procedure was 1.6 days. Mean International Prostate Symptom Score improved from 23.2 at baseline to 6.2 at 12 months (P <.0001). Mean International Prostate Symptom Score quality of life improved from 4.6 at baseline to 1.3 at 12-month follow-up (P <.0001). Significant improvements were seen in Qmax (12-month improvement of 12.5 cc/sec) and postvoid residual (drop of 171 cc in those with postvoid residual >100 at baseline). Antegrade ejaculation was maintained in 81% of sexually active men. No patient underwent a repeat procedure for BPH symptoms. There was a 2% de novo incontinence rate at 12 months, and 10 patients did require a transfusion postoperatively while 5 required take back fulgurations. At 12 months, prostate-specific antigen reduced from 7.1 ± 5.9 ng/mL at baseline to 4.4 ± 4.3 ng/mL. CONCLUSION: The Aquablation procedure is demonstrated to be safe and effective in treating men with large prostates (80-150 cc) after 1 year of follow-up, with an acceptable complication rate and without a significant increase in procedure or resection time compared to smaller sized glands. ClinicalTrials.gov number, NCT03123250.
引用
- Bhojani N, Bidair M, Zorn KC, et al. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. Urology. 2019. PMID: 31059728. doi:10.1016/j.urology.2019.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。